Toll-Like Receptor-Based Strategies for Cancer Immunotherapy

Table 3

A summary of recent ongoing clinical trials on TLR agonists started after 2019.

Target TLR	TLR agonist	Companion treatment	Conditions	Phase	Status	NCT number
TLR2/4	BCG, PPD, Typhim Vi	Chemotherapy, radiofrequency ablation	Colorectal cancer	I	Not yet recruiting	NCT04062721
TLR3	Poly-ICLC	Peptide vaccine, anti-CD40	Melanoma	I/II	Recruiting	NCT04364230
	Rintatolimod	Anti-PD-1, chemotherapy	Ovarian cancer recurrent	I/II	Recruiting	NCT03734692
TLR4	GLA-SE	N/A	Lymphoma, T cell, cutaneous	II	Withdrawn	NCT03742804
		Anti-CTLA-4, anti-PD-1, chemotherapy	Colorectal cancer metastatic	I	Withdrawn	NCT03982121
TLR7	BNT411	Anti-PDL-1, chemotherapy	Solid tumor, lung cancer	I/II	Recruiting	NCT04101357
	Imiquimod	Anti-PD-1, focused ultrasound ablation	Multiple solid tumors	I	Recruiting	NCT04116320
	RO7119929	Anti-IL-6 receptor	Biliary tract and liver cancer	I	Recruiting	NCT04338685
	SHR2150	Chemotherapy, anti-PD-1, anti-CD47	Solid tumor	I/II	Recruiting	NCT04588324
TLR7/8	TransCon	Anti-PD-1	Solid tumors	I/II	Recruiting	NCT04799054
TLR8	Motolimod	Anti-PD-1	Carcinoma, squamous cell	I	Recruiting	NCT03906526
TLR9	CMP-001	Anti-OX40	Pancreatic cancer, unresectable solid neoplasm	I/II	Not yet recruiting	NCT04387071
		Anti-PD-1	Melanoma	II	Recruiting	NCT04708418
						NCT04401995
	SD-101	Radiation therapy, anti-PD-1	Pancreatic cancer	I	Recruiting	NCT04050085
		Anti-OX40	Malignant solid neoplasm	I	Recruiting	NCT03831295
	Tilsotolimod	Anti-CTLA-4, anti-PD-1	Advanced cancer	I	Recruiting	NCT04270864

Indicated conditions are summarized in this table. Complete information is available via the provided ClinicalTrials.gov identifier (NCT number).